Library

Tipranavir

Tipranavir (TPV) is a nonpeptidic HIV-1 protease inhibitor manufactured by Boehringer Ingelheim under the trade name Aptivus. It is used as part of combination antiretroviral therapy for treatment-experienced patients with HIV-1 infection whose virus is resistant to more than one protease inhibitor. It is not approved for treatment-naïve patients.

Tipranavir molecular structure
Tipranavir molecular structure diagram from the DrugsPRO substance library.

Also known as: Aptivus

Classification

  • Chemical: Medicine

Effects

No data available for this section yet.

Routes of Administration

No route information available yet.

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu

Tipranavir - DrugsPRO vodič za tvari

Tipranavir: Tipranavir (TPV) is a nonpeptidic HIV-1 protease inhibitor manufactured by Boehringer Ingelheim under the trade name Aptivus. It is used as part of combination antiretroviral therapy for treatment-experienced patients with HIV-1 infection whose virus is resistant to more than one proteas

Related pages